



MEDICAL TIPS

DIABIZ TABLETS

Issue IX, No. 35, 2023

Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial

Chatur S, et al. Eur. Heart J. 2023; 44: 2930–2943.

- Safety and efficacy of Dapagliflozin according to background diuretic therapy and its influence on longitudinal diuretic use was evaluated in this study.
- Efficacy and safety of Dapagliflozin was consistent, irrespective of background diuretic use or dosing.
- Mean loop diuretic dosing increased with placebo, but remained relatively stable in the Dapagliflozin arm.
- Dapagliflozin significantly reduced new initiation of loop diuretics by 32% ($p < 0.001$), compared to placebo.

In patients with heart failure with mildly reduced or preserved ejection fraction, the clinical benefits of Dapagliflozin were consistent and safe with significant reduction in new loop diuretic requirement over time.

